Gene Sequencing and Immune Response - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Gene Sequencing

Immune Response

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

FEBRUARY 23, 2022

Code Bio’s 3DNA vectors are based on pieces of synthetic DNA linked together to form a scaffold that can carry a larger gene sequence than viral vectors, and according to the biotech don’t trigger an immune response which might cause side effects or limit the potential for re-dosing.

Gene Therapy

Gene Therapy Gene Gene Sequencing Immune Response

Medicago, GSK’s plant-made COVID jab clears phase 2

pharmaphorum

MAY 18, 2021

.” The interim phase 2 results show that two doses of the plant-derived jab stimulated neutralising antibody levels that are around 10 times higher than those in a panel of sera from patients recovering from COVID-19, with a similar response seen in adults and the elderly.

Vaccination

Vaccination Vaccine Immune Response Gene Sequencing

Zynteglo halt re-ignites viral vector safety concerns; analysts

pharmaphorum

FEBRUARY 22, 2021

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche’s Luxturna and Novartis’ Zolgensma. million in Europe.

Gene Therapy

Gene Therapy Gene Gene Sequencing Gene Expression

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Takeda grows in gene therapies again with $2bn Code Bio deal

Medicago, GSK’s plant-made COVID jab clears phase 2

Zynteglo halt re-ignites viral vector safety concerns; analysts

Webinars

Stay Connected